Today, the U.S. Food and Drug Administration approved the first liquid biopsy companion diagnostic that also uses next-generation sequencing (NGS) technology to identify patients with specific types of mutations of the epidermal growth factor...
Read More »
The University of Texas MD Anderson Cancer Center and Guardant Health today announced a multi-year partnership designed to accelerate comprehensive liquid biopsy technology into the standard of care in cancer treatment. The commercial, research and development agreement will make MD ...
Read More »
from BioNews by Isabel Steer – A study has cast doubts on the reliability of ‘liquid biopsies’ – blood tests that detect tumour mutations and are increasingly used to guide treatment. ‘Our findings indicate that the output from genetic testing can ...
Read More »
from Modern Healthcare by Erica Teichert – While many clinical trials fail because of bad results, nearly 1 in 5 fail because of low patient enrollment. In many cases, patients and their doctors don’t know they could be eligible to ...
Read More »
Guardant Health announced an agreement with Priority Health, one of Michigan’s largest health plans, that will bring its comprehensive liquid biopsy to oncologists treating Priority Health members with advanced cancers. Priority Health is the first U.S. health plan to adopt ...
Read More »
from San Francisco Business Times by Ron Leuty Guardant Health Inc. snagged nearly $100 million in funding from OrbiMed Advisors and others to aggressively expand its commercial and scientific work as competitors jump into the liquid biopsy market. The Redwood ...
Read More »
Exosome RNA Exosome RNA Research & Industry News
